JF

22

Nov2022

Fireside Chat: Trends to Watch in 2023
PDCI’s Lunch Time Educational Webinar Series

SAVE THE DATE: Join us on November 29 @ 12 p.m. for our last webinar of the year closing on the Top 3 Trends to Watch in Market Access in 2023. PDCI’s Directors will host a Fireside Chat to share their expertise on the trends to watch in 2023; John ... Read More

22

Nov2022

CADTH Pharmaceutical Reviews Update Includes Launch of RWE Guidance Consultation

On November 10, 2022, among other procedural updates included in the CADTH Pharmaceutical Reviews Update Issue 32, CADTH published its Real-World Evidence (RWE) Steering Committee’s anticipated Proposed RWE Reporting Guidance and initiated a public consultation on the guidance open now through January 6, 2023.What to know: The ... Read More

22

Nov2022

PDCI Well Wishes for Managing Director Kaitlyn Proulx

PDCI is congratulating its Managing Director, Kaitlyn Proulx, as she begins parental leave effective November 28, 2022.Since joining PDCI in 2010, Kaitlyn has demonstrated incredible strategic insights advising clients on optimizing pricing and market access in Canada. Since becoming Managing Director in 2017, Kaitlyn has ... Read More

13

Oct2022

PDCI’s Early Insights on PMPRB Draft Guidelines

On October 6, 2022, the Patented Medicine Prices Review Board (PMPRB) published its highly anticipated draft price regulatory Guidelines and has invited stakeholders to comment on its approach by December 5, 2022.While some aspects of these guidelines were anticipated, there are a number of new concerns and uncertainties ... Read More

06

Oct2022

PMPRB Releases Draft Guidelines and Launches 60-day consultation 

The Patented Medicine Prices Review Board (PMPRB) today, Ocober 6, 2022, released its draft PMPRB Guidelines with a 60-day consultation period running until December 5, 2022. PMPRB maintains that final Guidelines will be issued by end of this year and previously indicated its intent for new Guidelines ... Read More

19

Aug2022

PMPRB Implements its Interim Guidelines with Clarifications

On August 18, 2022, PMPRB announced its decisions regarding Price Regulation of patented medicines during the ‘Interim Period’, between July 1, 2022 and when a final set of price regulatory guidelines is published. The PMPRB has decided to move forward with earlier proposals drafted June 30th, 2022, and ... Read More

20

Jul2022

PDCI Launches Sharing Page for PMPRB Consultation Submissions

On June 30, 2022, PMPRB issued a Notice and Comment which published its Proposed Interim Guidance and invited stakeholder comments until July 18, 2022. This Interim Guidance outlines PMPRB’s intentions for regulating the prices of patented medicines in the “interim period” between the coming-into-force date ... Read More

30

Jun2022

PMPRB Updates: Proposed Interim Guidelines Published

PMPRB Launches Consultation on its Proposed Interim Guidance Today, June 30, 2022, PMPRB published a proposed set of Interim Excessive Price Guidelines and has invited stakeholders to comment on the approach before July 18, 2022. This Interim Guidance outlines PMPRB’s intentions ... Read More

28

Jun2022

PDCI welcomes François-Xavier Houde to the Team
 

François-Xavier has joined PDCI Market Access as a Senior Health Economist. He is responsible for leading the conception and development of strategic, evidence-based economic components for submission to Canadian Health Technology Assessment (HTA) bodies and public/private payers. Among other roles, he ensures that PDCI is ... Read More

20

Jun2022

PRESS RELEASE: PDCI’s Biopharmaceutical Ecosystem Index: Where does Canada Rank on its Attractiveness for New Medicine Launch

Ottawa, June 20, 2022: PDCI study finds Canada Ranks 10th on its Attractiveness for New Medicine Launch Launched today by PDCI Market Access, a new study finds Canada ranks 10th out of 14 countries ... Read More